Passage Bio, Inc. (PASG)

1,4700 +0,0100 (+0,68%) Al cierre: 04:00PM EDT

Passage Bio, Inc.

One Commerce Square
39th Floor 2005 Market Street
Philadelphia, PA 19103
United States
267 866 0311
https://www.passagebio.com

Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 58

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Dr. William Chou M.D.	President, CEO & Director	945,73k	N/A	1974
Mr. Edgar B. Cale Esq., J.D.	General Counsel & Company Secretary	804,69k	N/A	1964
Dr. Mark Forman M.D., Ph.D.	Chief Medical Officer	866,31k	N/A	1964
Dr. James M. Wilson M.D., Ph.D.	Co-Founder & Chief Scientific Advisor	N/A	N/A	1955
Ms. Kathleen Borthwick	Senior VP, CFO, Principal Financial Officer & Principal Accounting Officer	N/A	N/A	1977
Mr. Stuart M. Henderson	Senior Vice President of Corporate Development & Investor Relations	N/A	N/A	N/A
Eden Fucci	Senior Vice President of Technical Operations	N/A	N/A	N/A
Dr. Sue Browne Ph.D.	Senior Vice President of Research & Development	N/A	N/A	N/A
Dr. Karl Whitney Ph.D.	Senior Vice President of Global Regulatory Affairs	N/A	N/A	N/A

Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; and PBKR03, a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other program for huntington's disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. Passage Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

Gobierno corporativo

El ISS Governance QualityScore de Passage Bio, Inc., a día 1 de mayo de 2024, es 6. Las puntuaciones base son Auditoría: 3; Tablero: 5; Derechos de los accionistas: 8; Compensación: 8.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.